We found that the anti-TNF effect was associated with an absolute risk reduction in the risk of colorectal cancer (-2.1%, 95%CI -3.8% to -0.4%, p = 0.01) per 1 mg/L reduction in serum C-reactive protein. The gene discussed is CRP; the disease is colorectal cancer.